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Background
Lymphomas are the 5th most common cancer in the U.S.
and the most prevalent amongst these, low-grade B cell
lymphomas are incurable with standard therapy.
Previously, we completed three trials combining low-dose
radiotherapy (XRT) with intratumoral administration of a
TLR9 agonist (CpG) for patients with low-grade lym-
phoma, an approach we refer to as ‘in situ vaccination’.
We demonstrated induction of anti-tumor CD8 T cell
responses as well as clinical remissions of patients’ non-
irradiated sites of disease, lasting up to 4+ years. Not all
patients mounted CD8 T cell responses, possibly due to
the paucity of intratumoral dendritic cells (DC), given the
exceptional ability of these cells to endocytose dying
(e.g. irradiated) tumor cells for cross-presentation to anti-
tumor CD8 T cells. Increasing intratumoral DC may
improve the in situ vaccine.
Methods
Flt3L, the predominant DC differentiation factor,
induces tumor leukocyte infiltration and regression of
lymphoma pre-clinically, and a formulation of this cyto-
kine, CDX-301, mobilizes BDCA-1 and BDCA-3 DC
subsets as seen in a recently completed Phase I trial.
These DC subsets respond to several TLR agonists and
cross-present antigens more effectively than plasmacy-
toid DC. We have initiated a Phase I/II study of a new
iteration of the in situ vaccine, adding Flt3L-priming
and replacing the prior TLR9 agonist with the TLR3
agonist poly-ICLC (Figure 1A). The vaccine consists of:
Intratumoral Flt3L administration to increase DC
within the tumor
Low-dose XRT to induce immunogenic tumor cell
death and release tumor-associated antigens
Intratumoral poly-ICLC administration to activate
tumor antigen-loaded DC
Results
Six patients have been enrolled, and two patients have
completed therapy. Treated patients have shown marked
increase in both BDCA1 and BDCA3 intratumoral DC
after treatment with Flt3L as well as DC activation after
treatment with XRT and poly-ICLC. Both treated patients
have demonstrated partial remissions of untreated sites
per International Working Group criteria, persisting or
improving for >4 months after vaccination. These include
regressions of bulky lymph nodes (Figure 1B), as well as
peripheral blood (Figure 1C) and bone marrow disease. In
one patient with significant peripheral blood tumor bur-
den we observed >10-fold decrease in malignant B cells
with concurrent increase in non-tumor B cells, suggesting
some degree of cell specificity in the tumor-killing
mechanism. Adverse effects observed to date have been
mild.
Conclusions
Preliminary results suggest that the Flt3L-primed in situ
vaccine is feasible, safe and immunologically and clinically
effective. The study is ongoing.2Mount Sinai School of Medicine, USA
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Figure 1 Flt3L-primed insitu vaccine. A) Schema B) Regression of bulky (untreated) cervical and external iliac adenopathy and C) Decrease in
peripheral blood lymphoma (included in CD19+l-) cells with concurrent increase in non-tumor (CD+l+) B cells.
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